Skip to main content

Table 2 Drug treatment

From: Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study

 

Medication

n (%)

Total number of patients

3316

Concomitant administration of lipid-lowering drug during the study

 

No concomitant drug

3149 (95.0%)

Concomitant administration

167 (5.0%)

   statin

 

119 (3.6%)

   others

 

48 (1.4%)

diabetes drug administration before and during the study

 

   -Before-

-During-

 

   Not taken

Not taken

818 (24.7%)

   Not taken

Taken

521 (15.7%)

   Taken

Not taken

106 (3.2%)

   Taken

Taken

1871 (56.4%)

No concomitant diabetes drug during the study

924 (27.9%)

Concomitant treatment with diabetes drug during the study

2392 (72.1%)

Single treatment with:

 

   Sulfonylurea

 

732 (22.1%)

   Glinide

 

188 (5.7%)

   Alpha-glucosidase inhibitor

 

169 (5.1%)

   Biguanide

 

93 (2.8%)

   Thiazolidine

 

49 (1.5%)

   Insulin

 

156 (4.7%)

Combination therapies:

 

   Sulfonylurea + alpha-glucosidase inhibitor

 

229 (6.9%)

   Sulfonylurea + biguanide

 

212 (6.4%)

   Sulfonylurea + thiazolidine

 

91 (2.7%)

   Other

 

473 (14.3%)